AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30115454 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraclavicular radiotherapy
Number of subjects: 812
Study 30115454 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal mammary node radiotherapy
Number of subjects: 812
Study 30115454 — intervention group
Group type: COMPARATOR
Intervention: No internal mammary node radiotherapy
Number of subjects: 812
Study 30115454 — intervention group
Group type: EXPERIMENTAL
Intervention: Age < 40 years
Number of subjects: 812
Study 30115454 — intervention group
Group type: EXPERIMENTAL
Intervention: > T1 stage
Number of subjects: 812
Study 30115454 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative hormone receptor status
Number of subjects: 812
Study 30115454 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal mammary radiotherapy
Number of subjects: 812
Study 27126725 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 616
Study 24463933 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome score (MetS score)
Number of subjects: 3855
Study 22392934 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 40
Study 22392934 — intervention group
Group type: COMPARATOR
Intervention: No neoadjuvant therapy (Control)
Number of subjects: 40
Study 19158191 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (12.5-25 mg/d)
Number of subjects: 23
Study 19158191 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (50-75 mg/d)
Number of subjects: 23
Study 19158191 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 23
Study 19158191 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 23
Study 17229249 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus pioglitazone
Number of subjects: 0
Study 17229249 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus rosiglitazone
Number of subjects: 0
Study 16113372 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 72
Study 16113372 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IOP
Number of subjects: 72
Study 16113372 — intervention group
Group type: COMPARATOR
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 72
Study 11748600 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 22
Study 11748600 — intervention group
Group type: COMPARATOR
Intervention: Prolonged Exposure (PE)
Number of subjects: 22
Study 11748600 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR
Number of subjects: 22
Study 11748600 — intervention group
Group type: COMPARATOR
Intervention: PE
Number of subjects: 22
Study 9779521 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide 0.25 mg at bedtime
Number of subjects: 8
Study 9779521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7863254 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg/day for one year
Number of subjects: 581
Study 7863254 — intervention group
Group type: COMPARATOR
Intervention: Control group (no regular treatment)
Number of subjects: 581
Study 7863254 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg/day
Number of subjects: 581
Study 2511913 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual nitroglycerin tablets
Number of subjects: 20
Study 2511913 — intervention group
Group type: EXPERIMENTAL
Intervention: quickly dissolving nitroglycerin compound
Number of subjects: 20
Study 30975672 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut-directed hypnotherapy (HT)
Number of subjects: 100
Study 30975672 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (SMT)
Number of subjects: 100
Study 28301428 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) treatment, open-label induction at weeks 0 and 2 by body weight (≥40 kg: 160 mg and 80 mg; <40 kg: 80 mg and 40 mg), followed by randomized double-blind dosing (high or low dose every other week) to week 52.
Number of subjects: 0
Study 25082072 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane sweeping (swept)
Number of subjects: 800
Study 25082072 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane sweeping (swept) with ARM and oxytocin
Number of subjects: 800
Study 24325112 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 0.05 mg/kg (F0.5)
Number of subjects: 120
Study 24325112 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 0.1 mg/kg (F1)
Number of subjects: 120
Study 24325112 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 120
Study 22136978 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/losartan 5/50 mg fixed-dose combination
Number of subjects: 185
Study 22136978 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg monotherapy
Number of subjects: 185
Study 19338704 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and Vegetable Group (FVG)
Number of subjects: 209
Study 19338704 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 209
Study 17326994 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum total cholesterol (TC)
Number of subjects: 5
Study 17326994 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercholesterolemia prevalence
Number of subjects: 5
Study 15277147 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat plus 75 g oligosaccharides
Number of subjects: 24
Study 15277147 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat plus 50 g sodium caseinate
Number of subjects: 24
Study 15277147 — intervention group
Group type: COMPARATOR
Intervention: Fat alone
Number of subjects: 24
Study 15277147 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fat, oligosaccharides, and casein
Number of subjects: 24
Study 12066001 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapling
Number of subjects: 42
Study 12066001 — intervention group
Group type: COMPARATOR
Intervention: Suturing
Number of subjects: 42
Study 9649101 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative oral feeding
Number of subjects: 200
Study 9649101 — intervention group
Group type: COMPARATOR
Intervention: Traditional postoperative oral feeding
Number of subjects: 200
Study 7862856 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (15 micrograms/kg)
Number of subjects: 19
Study 7862856 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 19
Study 7862856 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine + Caffeine
Number of subjects: 19
Study 7862856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 2521699 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (3 mg/kg/wk)
Number of subjects: 40
Study 124247 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% spray solution
Number of subjects: 594
Study 124247 — intervention group
Group type: COMPARATOR
Intervention: 1% milk
Number of subjects: 594
Study 124247 — intervention group
Group type: COMPARATOR
Intervention: 1% solution
Number of subjects: 594
Study 124247 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 594
Study 30458639 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping application from origin to insertion (OI group)
Number of subjects: 45
Study 30458639 — intervention group
Group type: COMPARATOR
Intervention: No kinesio taping (control group)
Number of subjects: 45
Study 30458639 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping application from insertion to origin (IO group)
Number of subjects: 45
Study 28230615 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (1000 mg every 6 hours for 24 hours)
Number of subjects: 100
Study 28230615 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mL every 6 hours for 24 hours)
Number of subjects: 100
Study 28230615 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen
Number of subjects: 100
Study 28230615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 28230615 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen and Placebo
Number of subjects: 100
Study 25487613 — intervention group
Group type: EXPERIMENTAL
Intervention: Droxidopa (100-600 mg thrice-daily)
Number of subjects: 171
Study 25487613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 25487613 — intervention group
Group type: EXPERIMENTAL
Intervention: Droxidopa
Number of subjects: 171
Study 23594436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex hormone-binding globulin (SHBG)
Number of subjects: 2816
Study 21830512 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 dB manipulation of HRTF frequency bands
Number of subjects: 32
Study 21830512 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 dB manipulation of HRTF frequency bands
Number of subjects: 32
Study 21830512 — intervention group
Group type: COMPARATOR
Intervention: 0 dB manipulation of HRTF frequency bands
Number of subjects: 32
Study 18812446 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA plus conventional diagnostic procedures (CDPs)
Number of subjects: 202
Study 18812446 — intervention group
Group type: COMPARATOR
Intervention: Conventional diagnostic procedures (CDPs)
Number of subjects: 202
Study 18812446 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS probe within lesions
Number of subjects: 202
Study 18812446 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS probe adjacent to lesions
Number of subjects: 202
Study 18812446 — intervention group
Group type: EXPERIMENTAL
Intervention: TBNA
Number of subjects: 202
Study 18812446 — intervention group
Group type: EXPERIMENTAL
Intervention: TBB
Number of subjects: 202
Study 18812446 — intervention group
Group type: EXPERIMENTAL
Intervention: BW
Number of subjects: 202
Study 18812446 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA plus CDPs
Number of subjects: 202
Study 16452699 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive adaptation training
Number of subjects: 64
Study 16452699 — intervention group
Group type: COMPARATOR
Intervention: Generic environmental supports
Number of subjects: 64
Study 15086616 — intervention group
Group type: EXPERIMENTAL
Intervention: Biostite (test)
Number of subjects: 24
Study 15086616 — intervention group
Group type: COMPARATOR
Intervention: Bio-Oss (control)
Number of subjects: 24
Study 11699314 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% timolol in Gelrite (n = 23)
Number of subjects: 119
Study 11699314 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.5% timolol plus 2% dorzolamide (n = 22)
Number of subjects: 119
Study 11699314 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dorzolamide (n = 24)
Number of subjects: 119
Study 11699314 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine (n = 26)
Number of subjects: 119
Study 11699314 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin (control, n = 24)
Number of subjects: 119
Study 9129790 — intervention group
Group type: COMPARATOR
Intervention: Standard low-birth weight milk formula
Number of subjects: 27
Study 9129790 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-birth weight milk formula supplemented with nucleotides
Number of subjects: 27
Study 7711421 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal tretinoin (0.01%)
Number of subjects: 20
Study 7711421 — intervention group
Group type: COMPARATOR
Intervention: Commercial gel preparation (0.025% or 0.05%)
Number of subjects: 20
Study 31564388 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteinuria group (n=446)
Number of subjects: 2536
Study 31564388 — intervention group
Group type: COMPARATOR
Intervention: Non-proteinuria group (n=2048)
Number of subjects: 2536
Study 31533578 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable contraceptive (IC)
Number of subjects: 471
Study 31533578 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine device, sterilisation, or oral contraceptives
Number of subjects: 471
Study 31533578 — intervention group
Group type: COMPARATOR
Intervention: Contraceptive services
Number of subjects: 471
Study 31533578 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall contraceptive method mix
Number of subjects: 471
Study 31533578 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive discontinuation
Number of subjects: 471
Study 28511656 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiskeletonized ITA
Number of subjects: 60
Study 28511656 — intervention group
Group type: COMPARATOR
Intervention: Conventional pedicled ITA
Number of subjects: 60
Study 26297368 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimalist shoes
Number of subjects: 76
Study 26297368 — intervention group
Group type: COMPARATOR
Intervention: Control shoes
Number of subjects: 76
Study 23664773 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketamine 0.25 mg/kg
Number of subjects: 120
Study 23664773 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketamine 0.5 mg/kg
Number of subjects: 120
Study 23664773 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control Group)
Number of subjects: 120
Study 21241489 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated) (DAA) at doses of 6, 12, 18, or 24 μg/kg/hour
Number of subjects: 47
Study 21241489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 21241489 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (1 mg/kg body weight twice daily)
Number of subjects: 47
Study 18457329 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Exercise Training (PRET)
Number of subjects: 52
Study 18457329 — intervention group
Group type: COMPARATOR
Intervention: Standardized Therapeutic Exercise Protocol (TP)
Number of subjects: 52
Study 16524979 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant regimen (aprepitant, ondansetron and dexamethasone on day 1; aprepitant and dexamethasone on days 2‐3; dexamethasone on day 4)
Number of subjects: 0
Study 16524979 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant regimen
Number of subjects: 0
Study 16524979 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (ondansetron + dexamethasone on days 1‐4)
Number of subjects: 0
Study 12691509 — intervention group
Group type: EXPERIMENTAL
Intervention: Dianeal PD‐4 containing 0.1 g/L HA
Number of subjects: 13
Study 12691509 — intervention group
Group type: EXPERIMENTAL
Intervention: Dianeal PD‐4 containing 0.5 g/L HA
Number of subjects: 13
Study 12691509 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (Dianeal PD‐4, 1.36% glucose)
Number of subjects: 13
Study 11125779 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Track intervention (multisite, multicomponent preventive intervention including universal-level classroom program, social-skill training, academic tutoring, parent training, and home visiting)
Number of subjects: 0
Study 8656727 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient geriatric evaluation and management (GEM)
Number of subjects: 160
Study 8656727 — intervention group
Group type: COMPARATOR
Intervention: Usual outpatient primary care (UPC)
Number of subjects: 160
Study 1557981 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin surface modified (HSM) intraocular lenses (IOLs)
Number of subjects: 40
Study 1557981 — intervention group
Group type: COMPARATOR
Intervention: Regular polymethyl methacrylate (PMMA) intraocular lenses (IOLs)
Number of subjects: 40
Study 1557981 — intervention group
Group type: COMPARATOR
Intervention: Regular PMMA IOLs
Number of subjects: 40
Study 1557981 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin surface modified (HSM) IOLs and Regular PMMA IOLs
Number of subjects: 40
Study 2866558 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0
Study 2866558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2866558 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmethylimipramine
Number of subjects: 0
Study 2866558 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone suppression tests (DSTs)
Number of subjects: 0
Study 31070229 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cell (MSC) infusion, 2 million/kg intravenous infusions, administered twice in three patients.
Number of subjects: 6
Study 31070229 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cell (MSC) infusion
Number of subjects: 6
Study 28926306 — intervention group
Group type: EXPERIMENTAL
Intervention: weekly group art therapy (1.5 hours, 10 weeks)
Number of subjects: 57
Study 28926306 — intervention group
Group type: COMPARATOR
Intervention: waiting list group
Number of subjects: 57
Study 27770809 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose amitriptyline (25 mg)
Number of subjects: 150
Study 27770809 — intervention group
Group type: COMPARATOR
Intervention: Active placebo (benztropine mesylate, 1 mg)
Number of subjects: 150
Study 23682618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive cognitive behavioral therapy (8-day duration)
Number of subjects: 56
Study 22693121 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using hexaminolevulinate (HAL) 40 mM with 3-hour application
Number of subjects: 67
Study 22693121 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) for patients with CIN2
Number of subjects: 67
Study 19907355 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled epinephrine
Number of subjects: 0
Study 19907355 — intervention group
Group type: COMPARATOR
Intervention: Nasal decongestant
Number of subjects: 0
Study 18091473 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical traction during the first 2 weeks of a 6-week extension-oriented intervention
Number of subjects: 64
Study 18091473 — intervention group
Group type: COMPARATOR
Intervention: No mechanical traction during the first 2 weeks of a 6-week extension-oriented intervention
Number of subjects: 64
Study 16298288 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune of Life for Teens module (experimental I group with intensive training)
Number of subjects: 1580
Study 16298288 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune of Life for Teens module (experimental II group with nonintensive training)
Number of subjects: 1580
Study 16298288 — intervention group
Group type: COMPARATOR
Intervention: Control group (no application of the module)
Number of subjects: 1580
Study 12085364 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 805
Study 12085364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 805
Study 12085364 — intervention group
Group type: COMPARATOR
Intervention: Interferon
Number of subjects: 805
Study 12085364 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine plus interferon
Number of subjects: 805
Study 9468078 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 63
Study 9468078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 7665059 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubal anastomosis
Number of subjects: 33
Study 7665059 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 33
Study 7665059 — intervention group
Group type: COMPARATOR
Intervention: Control group (elective tubal ligation)
Number of subjects: 33
Study 7665059 — intervention group
Group type: EXPERIMENTAL
Intervention: Giessen-test
Number of subjects: 33
Study 2505716 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 0
Study 2505716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 57441 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor
Number of subjects: 30
Study 57441 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiological saline)
Number of subjects: 30
Study 31043657 — intervention group
Group type: EXPERIMENTAL
Intervention: Burdock tea (1.5 g three times a day)
Number of subjects: 161
Study 31043657 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 161
Study 27842468 — intervention group
Group type: EXPERIMENTAL
Intervention: FBO depression services
Number of subjects: 947
Study 25146233 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 66
Study 25146233 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 66
Study 24229362 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention program including educational, physical, and social interventions.
Number of subjects: 240
Study 21389149 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of RotaTeq and MenCC
Number of subjects: 247
Study 19273702 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline flushing via a positive-pressure cap
Number of subjects: 203
Study 19273702 — intervention group
Group type: COMPARATOR
Intervention: Standard flushing with heparin solution
Number of subjects: 203
Study 17290043 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg
Number of subjects: 234
Study 17290043 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 234
Study 17290043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 17290043 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (both doses)
Number of subjects: 234
Study 12768143 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal surgical exposure
Number of subjects: 146
Study 12768143 — intervention group
Group type: COMPARATOR
Intervention: Retroperitoneal surgical exposure
Number of subjects: 146
Study 10859289 — intervention group
Group type: EXPERIMENTAL
Intervention: L-5-methyltetrahydrofolate (MTHF) at 17 mg/d
Number of subjects: 50
Study 9106095 — intervention group
Group type: EXPERIMENTAL
Intervention: ARF treated liquefied porridge
Number of subjects: 28
Study 9106095 — intervention group
Group type: COMPARATOR
Intervention: Porridge diluted with water
Number of subjects: 28
Study 8244149 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with 5-epidoxorubicin emulsified in lipiodol
Number of subjects: 50
Study 8244149 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 50
Study 3510774 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (75 micrograms/kg)
Number of subjects: 15
Study 3510774 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (14 micrograms/kg/min)
Number of subjects: 15